• Healthcare

(1min)

A U.S. court of appeals has reportedly ruled that a whistleblower case against Novartis (NYSE:NVS) over alleged kickbacks involving its multiple sclerosis drug Gilenya can proceed.

The Second U.S. Circuit Court of Appeals in Manhattan ruled that whistleblower Steven Camburn can

Comments

Recommended For You

More Trending News

See More »

Create a free account to read the full article

Gain access to the world’s leading investment community.

Already registered?

By creating an account using any of the options above, you agree to the Terms of Use & Privacy Policy

or

Top Stocks 2025
Virtual Investing Forum

Join us on January 8 as our VP of Quant Strategy, Steven Cress, discusses his 2025 Top 10 Stock Picks.

These picks are selected using the proven data-driven approach that led his 2024 picks to significantly outperform the S&P 500.*

Register Now

*Performance as of December 6, 2024. Past performance is no guarantee of future results. Subject to Seeking Alpha’s Events Policy as available here: https://about.seekingalpha.com/events-policy.

About NVS Stock

Symbol	Last Price	% Chg
NVS	98.21	-0.20%

Market Cap

$195.00B

PE (TTM)

17.03

Yield

3.80%

Rev Growth (YoY)

8.92%

Short Interest

-

Prev. Close

$98.40

Compare to Peers

Related Stocks

Symbol	Last Price	% Chg
NVS	-	-
Novartis AG
AZN	-	-
AstraZeneca PLC
RHHBY	-	-
Roche Holding AG
PFE	-	-
Pfizer Inc.
MRK	-	-
Merck & Co., Inc.

Read Full Story: https://news.google.com/rss/articles/CBMiowFBVV95cUxNX3RCcDQ3T1RBTlQyWXYtb0dX...